STShannan R. Tujios

Shannan R. Tujios

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shannan R. Tujios has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of Hemophagocytic Lympho‐Histiocytosis ( HLH ) in the Setting of Adult Acute Liver Failure

    by Ahmad Anouti, Hamza Dahshi, Jody Rule, Christian Wysocki, William M. Lee, Shannan R. Tujios

    Hemophagocytic lympho‐histiocytosis (HLH) is a life‐threatening disease, only occasionally presenting as acute liver failure (ALF) in adults. HLH is challenging to diagnose. We reviewed the ALF Study Group (ALFSG) registry for suspected HLH subjects, as well as 184 with other ALF etiologies for cases that might have been missed, assessing standard laboratory tests, as well as interleukin‐18 (IL‐18) and soluble interleukin‐2 receptor (sIL‐2r), to determine the diagnostic utility of these biomarkers. We also calculated standard diagnostic algorithms (H score, HLH‐2004 diagnostic criteria) to assess their value. Within 3364 ALF subjects, only 14 were initially cited as HLH. Upon thorough review by an adjudication committee, 5/14 (35.7%) were considered definite, five probable, two possible, and two unlikely. Definite HLH patients had significantly higher ferritin ( p = 0.047), IL‐18 ( p = 0.003) and s‐IL2r ( p = 0.005) levels, H scores ( p < 0.001) and HLH scores ( p < 0.001). Other etiologies (APAP, DILI and viral) showed lower IL‐18 and sIL2r levels and scores, but overlapping ferritins. Several probable/possible HLH cases lacked complete data for scoring. No additional (missed) HLH cases were identified. HLH remains a rare cause of ALF. Biomarkers, particularly IL‐18 and sIL‐2r, appear of value. HLH and H scores were also helpful but limited when data was missing.

  • Open Access

    Opioid use after adult liver transplantation: Incidence, high-risk use, and adverse events in a large US cohort

    by Sarah R. Lieber, Olgert Bardhi, Yue Jiang, Alex R. Jones, Prajwal Gowda, Shannan R. Tujios, William Tirone, Madhukar S. Patel, Parsia Vagefi, Steven Hanish, et al.

    Background: Opioid use contributes to significant morbidity, posing specific risks to liver transplant recipients (LTRs). This study aimed to characterize outpatient opioid use before and after liver transplantation (LT) and identify risk factors for high-risk, incident, and chronic use and related complications. Methods: Adult LTRs were identified from 2006 to 2021 in IQVIA PharMetrics Plus for Academics, a claims database representative of the commercially insured US population. Opioid use was evaluated 30–365 days after LT; high-risk use was defined as >50 morphine milligram equivalents (MMEs) per day or concurrent opioid–benzodiazepine use. Factors associated with use, including high-risk use, were identified using multivariable logistic regression analysis. Landmark analyses assessed the association between outpatient opioid use 30–120 days post-LT and incident adverse events (eg, psychiatric, substance use, chronic pain, fractures/falls, digestive). Results: Among 1338 LTRs, 899 (67.2%) received outpatient opioid prescriptions >30 days post-LT, of whom 553 (41%) had incident use; 122 (13.6%) had high-risk opioid use. Factors significantly associated with high-risk use were female sex, pre-LT opioid use, and psychiatric disorder. Opioid use was significantly associated with increased adverse events 120–365 days post-LT; 59% of LTRs with opioid use within 1 year of LT developed complications compared to 39% of non-opioid users during this window (p<0.001). In adjusted landmark analyses, low/moderate opioid use within 30–120 days post-LT was associated with 1.87 times the hazard of complications compared to no opioid use at 120 days post-LT (95% CI: 1.14–3.07) and high-risk opioid use was associated with 2.87 (95% CI: 1.05–7.85) times the hazard. Conclusions: Post-LT opioid use is associated with increased risk of adverse events. Caution is needed in opioid prescribing beyond the perioperative period, particularly for those with preexisting psychiatric conditions.


  • Survivorship interventions after liver transplantation (LT): A systematic review of interventions targeting physical and psychosocial well-being after LT

    by Sarah R. Lieber, Alex R. Jones, Prajwal Gowda, Meena M. Tadros, Olgert Bardhi, Shari S. Rogal, Shannan R. Tujios, Arjmand R. Mufti, Thomas A. Kerr, Alvaro Noriega Ramirez, et al.

    Despite improved survival, liver transplantation (LT) recipients need interventions that promote survivorship including better quality of life. This systematic review describes the goals and quality of existing post-LT interventions to identify gaps in post-LT care. Published manuscripts and registered clinical trials were identified using MEDLINE, PsycINFO, Cochrane, and Scopus from inception to January 1, 2024. Articles and trials were included if they described patient-facing interventions targeting health behaviors, patient-centered outcomes, or preventative health. Data extraction and intervention quality were assessed using applicable trial standards. A total of 61 published manuscripts and 18 registered trials were identified in: (1) alcohol (n=14); (2) diet/nutrition (n=7), education (n=5), symptom management (n=11), preventative health (n=8), physical activity (n=19), and psychosocial issues (n=15). Most interventions were in the early phases of development or pilot testing and targeted the perioperative period up to 1-year post-LT, with fewer interventions targeting >1-year post-LT. There is good evidence to suggest that multidisciplinary programs with integrated psychiatric resources can reduce alcohol relapse post-LT; in-person multimodal interventions including individualized counseling, exercise prescriptions, and educational materials, improved strength, body composition, and quality of life. Multidisciplinary clinics integrating education, free resources, and clinical exams are beneficial in skin cancer prevention and cardiovascular risk modification. The best supported psychosocial interventions include support groups and in-person individualized counseling. Limited high-quality studies exist in diet/nutrition and education. For post-LT survivorship interventions, there is wide variation in intervention quality and limited investigation beyond 1 year post-LT. There is good evidence supporting multidisciplinary clinics/programs to prevent alcohol relapse, enhance physical activity, and facilitate cancer screening. There is limited data on promoting post-LT education, as well as social work and caregiver interventions. Future research should consider these areas for study; high-quality interventions need to incorporate stakeholder input, target later LT survivorship stages, and apply consistent definitions of patient-centered outcomes using validated measures.


  • Open Access

    Does Prior Bariatric Surgery Predispose to Acetaminophen-Related Acute Liver Failure?

    by Shannan R. Tujios, Isabel Wees, Ahmad Anouti, Michelle Gottfried, Jaime Almandoz, Valerie Durkalski, Jody A. Rule, Robert J. Fontana, William M. Lee, for the Acute Liver Failure Study Group

    INTRODUCTION: Prior small studies have suggested that patients with prior metabolic and bariatric surgery (MBS) may have increased susceptibility to acetaminophen (APAP)-related acute liver failure/acute liver injury (ALF/ALI). The aim of this study was to compare the presentation, etiology, and outcome of adult ALI/ALF patients who were enrolled in a prospective registry study with prior bariatric surgery to those without. METHODS: Among 3,364 ALF/ALI patients in the Acute Liver Failure Study Group registry enrolled between January 1998 and August 2019, 85 (2.3%) reported prior MBS. On review, 6 cases were deemed not ALF and excluded from the analysis. RESULTS: Among the 79 MBS ALF/ALI patients, 95% were female and 86% were White. Etiology included APAP-related ALF/ALI in 78.5% of the MBS group vs 49.3% in the non-MBS group (P < 0.001). The proportion of patients with MBS increased from 1.6% (1998–2008) to 3.4% in the later years (2009–2019) (P < 0.001). There were proportionately more unintentional overdoses in the MBS cohort (71% vs 52%, P < 0.001) with smaller median total APAP dose ingestion (6,500 mg vs 12,000 mg, P = 0.009). Although MBS patients had more severe encephalopathy at presentation, overall, 21-day and transplant-free survival between the groups were similar. DISCUSSION: ALF/ALI is more frequent in MBS patients than in the general population. APAP toxicity is the most common cause in MBS patients but not the only diagnosis observed. MBS may predispose to severe unintentional APAP liver injury at lower doses. Both MBS patients and providers should be aware regarding this potential risk of increased susceptibility to APAP hepatotoxicity.


  • Open Access

    Hidden Dangers: Herbal and Dietary Supplement Induced Hepatotoxicity

    by Jonathan Kwong-Shing Lin, Shannan R. Tujios

    Herbal and dietary supplements represent a multi-billion-dollar industry reportedly used by over half of American adults. However, these products are not regulated by the Federal Drug Agency and contain a wide range of contaminants, leading to over 50,000 adverse events each year. This review aims to highlight the widespread use and current regulatory status of herbal and dietary supplements, identify the presentation and diagnostic dilemmas faced with liver injury, and discuss the most common agents implicated in herbal and dietary supplement hepatotoxicity.


  • Top Cited Papers
    Open Access

    Future directions in acute liver failure

    by R. Todd Stravitz, Robert J. Fontana, Constantine Karvellas, Valerie Durkalski, Brendan McGuire, Jody A. Rule, Shannan Tujios, William M. Lee, for the Acute Liver Failure Study Group

    Acute liver failure (ALF) describes a clinical syndrome of rapid hepatocyte injury leading to liver failure manifested by coagulopathy and encephalopathy in the absence of pre-existing cirrhosis. The hallmark diagnostic features are a prolonged prothrombin time (ie, an international normalized ratio of prothrombin time of ≥1.5) and any degree of mental status alteration (HE). As a rare, orphan disease, it seemed an obvious target for a multicenter network. The Acute Liver Failure Study Group (ALFSG) began in 1997 to more thoroughly study and understand the causes, natural history, and management of ALF. Over the course of 22 years, 3364 adult patients were enrolled in the study registry (2614 ALF and 857 acute liver injury—international normalized ratio 2.0 but no encephalopathy—ALI) and >150,000 biosamples collected, including serum, plasma, urine, DNA, and liver tissue. Within the Registry study sites, 4 prospective substudies were conducted and published, 2 interventional (N-acetylcysteine and ornithine phenylacetate), 1 prognostic [13C-methacetin breath test (MBT)], and 1 mechanistic (rotational thromboelastometry). To review ALFSG’s accomplishments and consider next steps, a 2-day in-person conference was held at UT Southwestern Medical Center, Dallas, TX, entitled “Acute Liver Failure: Science and Practice,” in May 2022. To summarize the important findings in the field, this review highlights the current state of understanding of ALF and, more importantly, asks what further studies are needed to improve our understanding of the pathogenesis, natural history, and management of this unique and dramatic condition.


  • Autoimmune hepatitis presenting as acute liver failure: A 20-year retrospective review of North America

    by Thomas Enke, Sherry Livingston, Jody Rule, Todd Stravitz, Jorge Rakela, Nathan Bass, Adrian Reuben, Shannan Tujios, Anne Larson, Norman Sussman, et al.

    Autoimmune hepatitis is a common cause of acute liver failure. Treatment includes steroids for acute liver injury and liver transplantation in those who fail to respond or develop acute liver failure. The aim of this study is to further characterize acute liver failure secondary to autoimmune hepatitis and identify variables that predict 21-day transplant-free survival. This study included adults hospitalized with acute liver failure enrolled in the Acute Liver Failure Study Group Registry between 1998 and 2019 from 32 centers within the US. The etiology of all cases was reviewed by the Adjudication Committee, and all cases identified as autoimmune hepatitis were included. Acute liver injury was defined as an INR ≥2.0 without encephalopathy and acute liver failure as INR ≥ 1.5 with encephalopathy. Laboratory and clinical data were reviewed. Variables significantly associated with 21-day transplant-free survival were used to develop a multivariable logistic regression model. A total of 193 cases of acute liver failure secondary to autoimmune hepatitis were identified and reviewed. There were 161 patients (83.4%) diagnosed with acute liver failure on enrollment, and 32 (16.6%) developed acute liver failure during hospitalization. At 21 days, 115 (59.6%) underwent liver transplantation, 28 (14.5%) had transplant-free survival, and 46 (23.8%) died before liver transplantation. Higher admission values of bilirubin, INR, and coma grade were associated with worse outcomes. A prognostic index incorporating bilirubin, INR, coma grade, and platelet count had a concordance statistic of 0.84. Acute liver failure secondary to autoimmune hepatitis is associated with a high short-term mortality. We developed a model specifically for autoimmune hepatitis that may be helpful in predicting 21-day transplant-free survival and early identification of patients in need of expedited liver transplant evaluation.


  • Acute on Chronic Liver Failure

    by Mark R. Pedersen, Shannan R. Tujios

  • Transpapillary Gallbladder Stents Can Stabilize or Improve Decompensated Cirrhosis in Patients Awaiting Liver Transplantation

    by Shannan R. Tujios, Sahand Rahnama-Moghadam, Joseph B. Elmunzer, Richard Kwon, Amit G. Singal, Michelle A. Anderson, Erik-Jan Wamsteker, Jason R. Taylor, James Scheiman, Grace Elta, et al.

    Goals: To describe the short-term and long-term outcomes in 34 consecutive decompensated cirrhotic patients with symptomatic gallbladder disease undergoing transpapillary gallbladder stent (TGS) placement. Background: Endoscopic TGS placement is a minimally invasive means of treating symptomatic gallbladder disease in poor surgical candidates. Study: Between June 2005 and June 2011, 34 patients with cirrhosis and symptomatic gallbladder disease underwent attempted TGS placement. Results: Median patient age was 52 years, 56% were hospitalized, and 48% were listed for liver transplantation. The median model for end-stage liver disease (MELD) score was 15 (range, 6 to 40) and 88% were Child-Turcotte-Pugh class B/C. A double pigtailed stent was successfully placed in 94% of the patients. At 1-month follow-up, clinical improvement was noted in 82% of the treated subjects and the MELD scores in 14 of 22 (64%) evaluable subjects improved or stabilized. Actuarial transplant-free survival was 53% in the liver transplant candidates with a mean follow-up of 352 days, whereas survival was 44% in the 18 nontransplant candidates with a mean follow-up of 1.5 years. Periprocedural complications included pancreatitis in 5 patients, cholangitis in 3, and 1 patient with cystic duct perforation. In addition, 2 subjects had symptomatic bleeding from traumatic duodenal ulcerations 2 years after TGS placement that necessitated stent removal. Conclusions: Endoscopic TGS placement was technically feasible in 94% of decompensated cirrhotics and was associated with a relatively low rate of periprocedural (26%) and long-term complications (6%). Stabilization or improvement in clinical status and MELD scores was seen in the majority of treated patients.